DCM
BHVN

DAFNA Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

DAFNA Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-110,100
Closed -$16.6M – 90
2022
Q3 		$16.6M Hold
110,100
– – 4.48% 4
2022
Q2 		$16M Buy
110,100
+32,500
+42% +$4.15M 4.37% 3
2022
Q1 		$9.2M Buy
77,600
+19,500
+34% +$2.43M 2.4% 10
2021
Q4 		$8.01M Sell
58,100
-30,000
-34% -$3.81M 2.01% 12
2021
Q3 		$12.2M Sell
88,100
-6,000
-6% -$749K 3.25% 4
2021
Q2 		$9.13M Buy
94,100
+500
+0.5% +$40.6K 1.91% 9
2021
Q1 		$6.4M Buy
93,600
+11,500
+14% +$930K 1.52% 16
2020
Q4 		$7.04M Sell
82,100
-2,500
-3% -$212K 2.09% 11
2020
Q3 		$5.5M Sell
84,600
-3,000
-3% -$197K 1.79% 15
2020
Q2 		$6.4M Sell
87,600
-3,000
-3% -$160K 1.85% 16
2020
Q1 		$3.08M Buy
90,600
+15,900
+21% +$727K 1.29% 24
2019
Q4 		$4.07M Sell
74,700
-20,300
-21% -$1.01M 1.4% 19
2019
Q3 		$3.96M Hold
95,000
– – 1.49% 20
2019
Q2 		$4.16M Buy
95,000
+15,000
+19% +$846K 1.56% 19
2019
Q1 		$4.12M Hold
80,000
– – 1.78% 18
2018
Q4 		$2.96M Buy
80,000
+50,000
+167% +$1.8M 1.47% 23
2018
Q3 		$1.13M Buy
30,000
+6,500
+28% +$239K 0.46% 50
2018
Q2 		$929K Buy
+23,500
New +$746K 0.44% 54

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

DAFNA Capital Management's BHVN Position: Q4 2022 in Review

DAFNA Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 110,100 shares — an estimated $16.6M sold.

DAFNA Capital Management first reported a position in BHVN in Q2 2018 and held it in 18 quarters. The position peaked at $16.6M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • DAFNA Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • DAFNA Capital Management sold 110,100 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $16.6M.
  • DAFNA Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2018 and held it in 18 quarters.
  • DAFNA Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $16.6M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on DAFNA Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.